Form 4: Travere Therapeutics CEO Eric Dube Sells Shares Under 10b5-1 Plan

Travere Therapeutics CEO Eric Dube sold 11,375 shares of common stock at $24.04 per share on February 11, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On February 11, 2025, Eric M. Dube, the CEO of Travere Therapeutics, Inc., sold 11,375 shares of the company's common stock.
• The sale was executed at a price of $24.04 per share.
• This transaction was conducted under a pre-arranged trading plan that complies with Rule 10b5-1(c) of the Securities Exchange Act of 1934.
• Following the sale, Dube directly owns 419,173 shares of Travere Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document describes a routine stock sale by the CEO under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment, but rather a planned transaction.

Industry Context

Insider sales are a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares without raising concerns about trading on material non-public information. Investors often monitor insider transactions for signals about a company's prospects, but sales under pre-arranged plans are generally viewed as less informative than discretionary trades.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates

Keywords

Travere Therapeutics, Eric Dube, stock sale, Form 4, 10b5-1 plan, insider trading, equity securities